Ipragliflozin

Research use only, not for human use.

A highly potent and selective SGLT2 inhibitor with IC50 of 14 nM for hSGLT2.

A highly potent and selective SGLT2 inhibitor with IC50 of 14 nM for hSGLT2; shows 254-fold selectivity over hSGLT1; reduces blood glucose levels in a dose-dependent manner in diabetic models KK-A(y) mice and STZ rats.Diabetes Approved

Cell Viability Assay Cell Line:MCF-7 human breast cancer cell lines Concentration:1, 10, 50 μM Incubation Time:24, 48, 72, 96 hours Result:Decreased the number of MCF-7 cells in a dose-dependent manner.

Animal Model:Single Administration Streptozotocin (STZ; 50 mg/kg)-induced type 1 diabetic rats and KK-Ay type 2 diabetic mice Dosage:0.1-1 mg/kg Administration:Single oral administration in the fed condition. Blood glucose levels were then measured for 8 h under fasting conditions.Result:Dose-dependently lowered blood glucose levels, and this effect was significant at all tested doses.Animal Model:Repeated Administration Streptozotocin (STZ; 50 mg/kg)-induced type 1 diabetic rats Dosage:0.3 and 1 mg/kg Administration:Administration orally once daily (at night) for 4 weeks. Result:Significantly reduced the levels of HbA1c and blood glucose. Pancreatic insulin content was significantly increased at a dose of 1 mg/kg. Urinary glucose excretion was increased dose-dependently, and this was significant at the 1 mg/kg dose.

ASP1941 | ASP 1941 | ASP-1941

GPCR/G Protein

SGLT

SGLT2

Metabolic Disease

Diabetes

761423-87-4

404.4518

C21H21FO5S

>98% (HPLC)

10 mM in DMSO

O[C@H]1[C@H](C2=CC=C(F)C(CC3=CC4=CC=CC=C4S3)=C2)O[C@H](CO)[C@@H](O)[C@@H]1O

D-Glucitol, 1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-, (1S)-

(-20℃)

With Ice Pack

≥ 2 years